- 1 TITLE: The Colorado Heart Failure Acuity Risk Model (CHARM) Score: A Mortality Risk
- 2 Model for Waitlisted Cardiac Transplant Patients
- 3

4 AUTHORS:

- 5 Rachel D. Murphy, MD¹
- 6 Sarah Y. Park, MD²
- 7 Larry A. Allen, MD, MHS²
- 8 Amrut V. Ambardekar, MD²
- 9 Joseph C. Cleveland, Jr., MD³
- 10 Michael T. Cain, MD³
- 11 Bruce Kaplan, MD^{4,5}
- 12 Jordan R.H. Hoffman, MPH, MD³
- 13 John S. Malamon, PhD^{4,5}
- 14

15 **AFFILIATIONS:**

- ¹⁶ ¹University of Colorado Anschutz Medical Campus, Department of Medicine
- ¹⁷²University of Colorado Anschutz Medical Campus, Department of Medicine, Division of
- 18 Cardiology
- ¹⁹ ³University of Colorado Anschutz Medical Campus, Department of Surgery, Division of
- 20 Cardiothoracic Surgery
- ⁴University of Colorado Anschutz Medical Campus, Department of Surgery, Division of
- 22 Transplant Surgery
- ⁵Colorado Center for Transplantation Care, Research and Education (CCTCARE)
- 24

25 **WORD COUNT:** 2,987

26 **LAST REVISION:** 08/10/2023

27 CORRESPONDING AUTHOR:

- 28 John Stephen Malamon, PhD
- 29 University of Colorado, Anschutz Medical Campus
- 30 1635 Aurora Ct., Aurora CO 80045
- 31 Phone: 1-720-848-9063
- 32 Email: john.malamon@cuanschutz.edu

33 **KEY POINTS:**

34 Question: Can pre-operative patient characteristics be used to develop a formal system 35 to accurately estimate, rank, and predict the relative short-term mortality of waitlisted 36 heart transplant patients?

37

38 **Findings:** Using twelve patient attributes, we derived three linear regression equations 39 to accurately predict the 30-day, 90-day, and 1-year mortality of waitlisted heart 40 transplant patients. We developed and calibrated a seven-tiered risk index for each 41 model that was 99% correlated to the observed mortality rate. Using several 42 independent validation methods, we achieved extreme sensitivity (>98%) in ordinally 43 ranking patient groups who were more likely to survive 30 days on the waitlist. Model 44 performance was measured using the area under the receiver operating characteristic 45 (ROC) curve. Using six interaction terms, the area under the ROC curve was 96.4% 46 (30-day), 90.4% (90-day), and 78% (1-year).

47

Meaning: Our models accurately discriminate among patient subgroups who are more likely to die while waitlisted. Because our tiered ranking system is simple, extremely sensitive, and well calibrated, it is ideal for prioritizing waitlisted heart transplant patients based on a well-defined medical urgency score. These models are generalized and therefore extensible to defining medical urgency in larger patient populations experiencing end-stage heart failure.

54

55

56 **ABSTRACT**:

Importance: Although the Organ Procurement and Transplantation network provides structured policies and guidance for waitlisted cardiac transplant patients, the heart transplantation community lacks a mathematical model that can accurately estimate the short-term risk of death associated with being waitlisted. Importantly, the CHARM score provides a risk management and ranking system for patients based on a well-defined and sensitive medical urgency metric.

Objective: We had three primary objectives in completing this study. First, to increase 63 64 relevance and applicability, we selected patient attributes that were clinically justified 65 and readily available. Second, we designed and implemented an intuitive, formal 66 system that accurately defined the relative risk of death while being waitlisted at 30-day, 67 90-day, and 1-year censoring periods. Third, we developed and validated a medical urgency metric that is intuitive, practical, and can be implemented nationally. 68 69 **Design:** We present a multivariable, prognostic model and risk management strategy 70 for adult waitlisted heart transplant patients (N=1,965) from the Scientific Registry of 71 Transplant Recipients (SRTR) database that were waitlisted from January 1, 2008, to 72 September 2, 2022. To independently validate each model, we randomly split this 73 cohort into a discovery set (N=1,174) and validation set (N=784). Twelve independent 74 patient attributes were selected, and three linear regression formulas were derived to 75 estimate and rank the relative risk of dying while waitlisted. Four independent validation 76 methods were used to measure each model's performance as a classifier and ranking 77 system.

78 **Setting:** The United States

79 Participants: This cohort (N=1,965) consisted of adult heart transplant candidates 80 without missing laboratory data who were placed on the waitlist from January 1, 2008, 81 to September 2, 2022. Patients listed for multi-organ transplantation were excluded. 82 Patients with missing laboratory data were analyzed independently. 83 **Exposures:** The short-term risk of death remaining on the heart transplant waitlist. 84 **Main Outcomes and Measures:** The primary outcome of this study was the design, 85 development, and validation of a formal risk management system for waitlisted heart 86 transplant candidates experiencing end-stage heart failure. We derived three linear 87 regression formulas and calibrated a seven-tiered risk index to accurately rank patients 88 who were more likely to die on the waitlist at 30-day (30D), 90-day (90D), and 1-year 89 (1Y) censoring periods. Four independent validation methods were used to measure 90 each model's classification and ranking performance. 91 **Results:** Using six interaction terms, we applied the 5-fold cross-validation procedure to 92 the CHARM to discover an area under the ROC curve of 96.4%, 90.4.%, and 78% for 93 the 30D, 90D, and 1Y models, respectively. The mean positive predictive values of the 94 tiered risk system were 99.2% (30D), 94.1% (90D), and 88% (1Y). Risk indices for all 95 three models were >99% correlated to the observed mortality rate across the seven

96 tiers for the 30D, 90D, and 1Y models.

97 **Conclusions and Relevance:** We designed, implemented, and validated an intuitive 98 and formal risk scoring and ranking system which is ideal for prioritizing waitlisted heart 99 failure patients based on a well-defined medical urgency metric. The CHARM score 100 provides extreme sensitivity in predicting short-term mortality outcomes. The CHARM 101 score is extensible to larger patient populations experiencing end-stage heart failure.

102 1. INTRODUCTION

103 The Organ Procurement and Transplantation Network (OPTN) has worked to develop a 104 cardiac transplant allocation system that distributes donor hearts to the most critically ill 105 patients¹. The 2018 policy revision created a 6-tiered "status"-based stratification 106 system that attempted to encompass the increasing complexity of managing critical 107 cardiac illness. However, this policy has been critiqued for its subjectivity and 108 heterogeneity in accurately discriminating patient risk while on the waitlist. For example, 109 a large percentage of transplant candidates are now stratified to Status 1 or Status 2 by 110 exception rather than by the standard criteria, which can be modified by a physician's practice². Importantly, studies have demonstrated that the 2018 policy revision is 111 associated with a significant reduction in post-transplant survival^{3,4}. A formal prognostic 112 model that accurately stratifies waitlisted end-stage heart failure (HF) patients based on 113 114 medical urgency is nonexistent. The need for such a model was recently highlighted by 115 Pelzer *et al.*, who determined the current allocation system had only a moderate ability 116 to successfully rank transplant candidates according to medical urgency⁵.

117

While useful prognostic tools for patients with HF have been introduced, such as the Heart Failure Survival Score⁶ and the Seattle Heart Failure Model⁷, they have not accurately predicted waitlist mortality⁸. The Ottawa Heart Failure Risk Scale provides a risk stratification tool designed for acute heart failure patients in emergency departments⁹. However, this score has not been applied to or validated against a waitlisted heart transplant patient population. Similarly, the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) risk score performs well for HF patients with

preserved ejection fraction, but it has not been externally validated for reduced ejection
 fraction, which would exclude most of the population on a transplant list¹⁰.

127

128 Predictive models have been successfully implemented in other organ transplant systems. The Model for End-stage Liver Disease including Sodium or MELD-Na score 129 130 for liver transplantation accurately predicts 90-day patient waitlist mortality and is the most significant metric in liver allocation¹¹. A similar model is desperately needed in 131 132 cardiac transplantation to accurately prioritize the most critically ill patients. We used the 133 Scientific Registry of Transplant Recipients (SRTR) database to develop and validate three predictive mortality models for waitlisted patients with end-stage HF. Our models 134 135 utilize objective physiological data to determine the most urgent heart transplant 136 candidates and stratify their relative risk of waitlist mortality at 30 days, 90 days, and 1 137 year.

138

139 **2. METHODS**

140 **2.1 Data sources**

This study utilized retrospective data from the SRTR. The SRTR system includes data
on all donors, waitlisted candidates, and transplant recipients in the US, submitted by
the members of OPTN¹². The Health Resources and Services Administration, U.S.
Department of Health and Human Services provides oversight to the activities of the
OPTN and SRTR contractors. The data reported here have been supplied by the
Hennepin Healthcare Research Institute as the contractor for SRTR. The interpretation

and reporting of these data are the responsibility of the author(s) and in no way should
be seen as an official policy of or interpretation by the SRTR or the U.S. Government.

149

150 **2.2 Study population**

151 The study population included adult waitlisted cardiac transplant patients with complete 152 laboratory results who registered for a single-organ heart transplant (N=1,965) between 153 January 1, 2008, and September 2, 2022. Supplemental Figure 1 provides a participant workflow diagram with the number of participants retained for each exclusion 154 155 criterion. All steps in this analysis were conducted for 30-day (30D), 90-day (90D), and 156 1-year (1Y) all-cause mortality. Survival times for waitlisted candidates started at the 157 date of listing and were censored at the date of death and upon removal from the 158 waitlist. The population was randomly split (60%/40%) into two cohorts, a discovery set 159 (N=1,179) and a validation set (N=786). The discovery set was used for variable 160 selection, the generation of three linear regression equations, and the creation of a 161 tiered risk index. The validation set was used to independently evaluate each model's 162 performance in predicting mortality outcomes and ranking patients' relative risk of death. 163

164 **2.3 Study Ethics**

Informed consent was obtained for all study participants. This study was reviewed by an ethical committee (Colorado Multiple Institutions Review Board) and was determined to be non-human subjects research. This study was not grant funded. The authors do not have any conflicts of interest to disclose. All authors reviewed the results and approved the final manuscript.

170

171 2.4 Statistical approach

172 2.4.1 Missingness and Sensitivity Analysis

173 We compared the patient populations with some missing laboratory data (N=20,991) to

those without missing data (N=1,965). For continuous variables, two-way ANOVA was

175 used to test the observed differences in patient characteristics and the twelve

176 independent variables used in this study. The chi-squared test was used to measure the

177 significance of categorical and indicator (binary) variables. Missing data were significant

178 in the laboratory variables; therefore, we analyzed missingness patterns and performed

three related sensitivity analyses using: 1) participants without missing data (N=1,965);

180 2) all participants with missing laboratory data (N=22,949); and 3) all participants with

181 missing laboratory values imputed (N=22,949). The Multivariate Imputation by Chain

182 Variables or MICE algorithm was used to impute missing values.

183

184 **2.4.2** Clinical Variable Selection and Importance

185 For clinical applicability, we selected twelve patient variables that were readily available 186 and clinically justified. These twelve variables should also exhibit discriminating power 187 and low collinearity. To measure collinearity, we calculated the Pearson's cross-188 correlation coefficient (R) and variance inflation factor (VIF) for all twelve independent 189 variables. Low collinearity was defined as two independent variables with an R value 190 less than 0.7. The VIF is used to determine the correlation between independent 191 variables in a logistic regression model. A VIF of 1 provides no correlation, whereas values above 2.5 indicate considerable multicollinearity¹³. Using the discovery set, we 192

- 193 measured and ranked the relative importance of each patient variable via the
- unsupervised Random Forest (RF) algorithm¹⁴ with the number of days survived as the
- 195 outcome. The RF algorithm provided an orthogonal method for comparing the relative
- 196 effect of each independent variable used in these models.
- 197

198 2.4.3. Independent Variable Definitions

199 Life Support refers to any waitlisted heart transplant recipient who received any cardiac 200 support prior to transplant including intravenous (IV) inotropic infusion, or any circulatory 201 support device such as right ventricular assist devices (RVAD), left ventricular assist 202 devices (LVAD), total artificial hearts (TAH), extracorporeal membrane oxygenation (ECMO), or intra-aortic balloon pumps (IABP)¹⁵. The Ventilator variable refers to the 203 204 need for any mechanical ventilation prior to transplant. The use of mechanical 205 ventilators has been shown to significantly increase patients' risk of death posttransplant¹⁶. The Prior Cardiac Surgery indicator variable includes patients with any 206 207 history of cardiac surgery.

208

209 2.4.4 Regression Formulas for Calculating Patient Risk Scores

We set out to develop a short-term prognostic model to formally define a patient risk score also known as the CHARM score based on a patient's estimated likelihood of death while waitlisted. Thus, we constructed three linear regression equations using the logistic link function for 30D, 90D, and 1Y mortality outcomes (**Equations 1-3**). All laboratory values were transformed to the logarithmic scale prior to calculation. We calculated CHARM scores for all patients in the discovery set to develop these

- equations. For consistency across the models, we used **Equation 4** to normalize
- 217 CHARM scores to range from 0 to 1.
- 218

219 **2.4.5** Model Calibration and the Tiered Risk Index

220 A well calibrated ranking system is required to accurately estimate the relative medical 221 urgency of waitlisted heart transplant patients. Thus, we developed a seven-tiered risk 222 index system based on the CHARM score which ranges from one to seven. We then fit 223 the risk tiers to the observed mortality rate to maximize the statistical discrimination in 224 ranking the relative mortality likelihood observed in these patient subgroups or indices. 225 We defined tiered risk thresholds and calibrated each regression model by maximizing 226 the goodness-of-fit between the observed mortality and the risk indices, which are 227 positively correlated. Here, we calculated the goodness-of-fit (R) using linear

regression.

229

230 **2.4.6** Validating Dichotomous Outcomes using Logistic Regression

We measured each model's performance in predicting mortality events at three
censoring periods using 5-fold cross-validation (in-sample) and supervised sample holdout validation (out-sample) using the validation set. We evaluated both additive models
and those using interaction terms. Age, Albumin, Creatinine, Circulatory Support,
Previous Transplant, and Prior Cardiac Surgery were the interaction terms. For sample
hold-out validation, we used the supervised Random Forest classification method¹⁴ with
70 trees. Priors were calculated using the discovery set and predictions were

independently validated using the validation set. Finally, we calculated the area under
 the ROC curve¹⁷ for all three models.

240

241 **2.4.7 Validating the Seven-Tiered Risk Index System**

242 To validate our risk classification system using a univariate test, we leveraged the Cox proportional-hazard regression (CPHR) method¹⁸ to measure tier performance in terms 243 of survival time. Here the unit of measurement was the concordance index¹⁹. To further 244 245 evaluate the performance of the tiered risk system, we used **Equation 5** to calculate the 246 rank precision or the positive predictive value (PPV) for each risk tier as compared to all others. A true positive (TP) occurred when a patient with a lower risk index outlived a 247 248 patient in any higher tier. A false positive (FP) occurred when a patient with a higher risk index outlived a patient in any lower tier²⁰. All analyses were performed using the R 249 statistical language version 4.1.2²¹. 250

251

252 3. RESULTS

253 **3.1 Population Characteristics**

The discovery, validation, and total patient population characteristics are depicted in

Table 1. The mean (SD) age of the 1,965 study participants with no missing laboratory

- data was 48.5 (14.5) years; 1,432 (73.1%) participants were male, 1,402 (71.6%) were
- 257 White/Caucasian, 374 (19.1%) were Black or African American, 104 (5.3%) were
- Hispanic or Latino, 56 (2.9%) were Asian, 9 (0.5%) were Native Hawaiian or Other
- 259 Pacific Islander, and 6 (0.3%) were American Indian or Alaska Native. In summary,

260	there were no statistically	significant differences in the	patient characteristics or
	1		

independent variables when comparing the discovery set to the validation set.

262

263 **3.2.** *Missingness and Sensitivity Analysis*

264 Supplemental Table 1 summarizes the missing data for the twelve independent 265 variables used in this model. More than 90% of total waitlisted patients were missing 266 laboratory data. Supplemental Table 2 provides the patient population characteristics for those with some missing data (N=20,991) and those without missing data (N=1,965). 267 268 On average, patients without missing data were younger and more likely to be female or 269 Caucasian. Statistically significant differences between the two cohorts were observed 270 in five of the twelve independent variables. **Supplemental Figure 2** provides a missing 271 value map for all independent variables. In summary, Age, Circulatory Support, 272 Previous Transplant, Sodium, and Ventilator were missing at random. The other seven variables were missing completely at random²². Supplemental Table 3 provides the 273 274 AUC of the ROC for participants without missing data, with missing data, and with 275 missing values imputed.

276

277 3.3 Variable Selection and Importance

278 **Supplemental Table 4** provides the relative variable importance in the RF model,

279 measured by the Gini Index, a statistic dispersion value notated as the Increase in Node

280 Purity (IncNodePurity). These data were normalized using **Equation 4** and are useful

for ranking the relative importance of each independent variable. All logistic regression

coefficients, p-values, and VIF values are provided in **Supplemental Table 5**. The

- 283 correlation coefficients of the independent variables were below the absolute value of
- 0.21, and VIF values ranged from 1 to 1.532 (Figure 1). No significant co-linearity was
- 285 observed in the variables or models.
- 286
- 287 3.4 Mathematical Formulas
- 288 Equation 1: The 30-day CHARM score

$$\begin{aligned} \textbf{CHARM}_{30D} &= \sum_{i=1}^{P} 10.5 + (0.0129 * Age_i) - (0.116 * Cardiac Surgery_i) \\ &+ (0.6512 * Life Support_i) - (0.7136 * log(Albumin_i)) \\ &+ (0.4314 * log(Creatinine_i)) - (15.83 * Ventilator_i) \\ &+ (1.088 * Previous Transplant_i) + (0.0001 * log(BNP_i)) \\ &+ (0.6119 * log(AST_i)) - (2.992 * log(Sodium_i)) \\ &+ (0.5185 * log(Bilirubin_i)) - (0.0711 * Waitlist Days_i) \end{aligned}$$

289 290

Equation 2: The 90-day CHARM score

$$\begin{aligned} \textbf{CHARM}_{90D} &= \sum_{i=1}^{P} -6.61 + (0.076 * Age_i) + (0.123 * Cardiac Surgery_i) \\ &+ (1.111 * Life Support_i) + (0.76 * log(Albumin_i)) \\ &+ (0.423 * log(Creatinine_i)) + (0.336 * Ventilator_i) \\ &+ (0.029 * Previous Transplant_i) - (0.205 * log(BNP_i)) \\ &+ (0.12 * log(AST_i)) - (0.124 * log(Sodium_i)) \\ &+ (0.089 * log(Bilirubin_i)) - (7.433 * Waitlist Days_i) \end{aligned}$$

291

292 Equation 3: The 1-year CHARM score

$$\begin{aligned} \textbf{CHARM}_{1Y} &= \sum_{i=1}^{P} -2.485 + (0.1 * Age_i) + (0.164 * Cardiac Surgery_i) \\ &+ (0.814 * Life Support_i) + (0.285 * log(Albumin_i)) \\ &+ (0.554 * log(Creatinine_i)) + (0.134 * Ventilator_i) \\ &+ (0.013 * Previous Transplant_i) - (0.148 * log(BNP_i)) \\ &+ (0.255 * log(AST_i)) - (0.175 * log(Sodium_i)) \\ &+ (0.136 * log(Bilirubin_i)) - (1.382 * Waitlist Days_i) \end{aligned}$$

293

294 Equation 4: Normalization by scaling between 0 and 1

$$NPRS = \sum_{i=1}^{P} \frac{(PRS_i) - min(PRS_{i:P})}{max(PRS_{i:P}) - min(PRS_{i:P})}$$

295

296 Equation 5: Positive Predictive Value of the Tiered Risk System

$$PPV = TP/(TP + FP)$$

297

3.4 Model Calibration and the Tiered Risk Index

The observed mortality rate is presented in **Figure 2** per risk index as a function of the CHARM score. **Supplemental Figures 3-5** provide the CHARM score distributions for each model. For the 90-day model, Risk Index (RI) 1 had an observed mortality rate of 1.52%, RI 2 had a mortality rate of 3.54%, RI 3 had a mortality rate of 7%, RI 4 had a mortality rate of 11.25%, RI 5 had a mortality rate of 13.5%, RI 6 had a mortality rate of 20.8%, and RI 7 had a mortality rate of 26.5%. The risk indices were >99% correlated to the observed mortality rate across the seven tiers for all three models.

306

307 **3.5 Logistic Regression for Predicting Short-term Mortality Outcomes**

308 The 5-fold cross-validation procedure produced an AUC of 94.8%, 86.7.%, and 74.2%

309 for the 30D, 90D, and 1Y additive models, respectively (**Supplemental Figures 6-8**).

Using interaction terms, the AUC was 96.4%, 90.4%, and 78%, respectively (**Figure 3**).

311 Sample hold-out validation produced an AUC of 93.8%, 92.5%, and 74.7% for the 30D,

312 90D, and 1Y additive models, respectively (Supplemental Figures 9-11). In summary,

these models and the tiered risk system provide a reliable and highly accurate

314 methodology for ranking the short-term survival of waitlisted heart transplant patients.

315 **3.6 Validation of the Seven-Tiered Risk Index System**

316 Using the validation cohort, we found that the PPV of the seven-tiered risk index system ranged from 98.3% to 100% (30D), 83.7% to 100% (90D), and 0.668% to 100% (Table 317 318 **2**). The mean PPVs were 99.2% (30D), 94.1% (90D), and 88% (1Y). Using the Cox 319 proportional-hazard regression methodology as a univariate test where the unit of 320 measurement was the risk index, we found a significant difference in survival times by 321 risk tier (**Supplemental Figure 12-14**). For example, CPHR revealed that a patient with a RI of 7 had a 26% chance of death after 90 days on the waitlist, while a patient with a 322 323 RI of 1 had about a 2% risk of death. The mortality rates for the risk indices provided in 324 Figure 2 are nearly identical to the inverse survival rates provided by the CPHR 325 analysis.

326

327 **4. DISCUSSION**

There is currently no model that accurately stratifies waitlisted cardiac transplant patients based on medical urgency. Formal pre-transplant predictive models have been successfully developed in liver transplantation. Evans *et al.* demonstrated an overall 1year survival rate increase of 18% in high-acuity patients in the 15 years following the national implementation of the MELD-Na score²³. A similar metric is needed for cardiac transplant to prioritize the most critically ill waitlisted patients.

334

To this end, we created the Colorado Heart failure Acuity Risk Model or CHARM score.

336 The models provided herein precisely rank patient subgroups based on waitlist mortality

337 with mean PPVs of 99.2% (30D), 94.1% (90D), and 88% (1Y). They demonstrate

excellent accuracy with AUC values of 96.4%, 90.4%, and 78%, respectively. While

previous scores or models have aimed to assess heart failure illness severity, the
 CHARM score is the first to present this level of accuracy and predictive performance
 among waitlisted HF patients.

342

343 The CHARM score is intended to be used in cardiac transplant candidates at the time of 344 listing. The 90D time frame will allow for frequent reevaluation while maintaining a high 345 degree of prediction accuracy. The CHARM score can substantially improve heart allocation within the current "status"-based system by providing an objective prognostic 346 347 measurement of medical urgency. The CHARM score will inform the continuous 348 distribution for CD system, as it utilizes a framework that is point-based rather than 349 "status"-based, in which candidates are prioritized for transplant through designation of 350 a composite score from a variety of attributes. Staged implementation of the CD system 351 is currently underway with anticipated completion of the heart allocation system within 352 the next few years. A substantial portion (25%) of the lung transplant composite score is 353 comprised of estimated waitlist mortality, further emphasizing the importance of pre-354 transplant mortality estimates for assessing patient acuity. The CHARM score provides 355 a simple, accurate measure of pre-transplant mortality that can easily be incorporated 356 into a heart transplant composite score.

357

The twelve independent patient variables incorporated into the CHARM score were chosen for their objectivity, clinical availability, and relevance to cardiac illness. Each variable was determined to significantly contribute to the predictive value of waitlist mortality. Laboratory values were selected for their evaluation of crucial organ function

362 in the setting of severe HF. A large meta-analysis of sixty-four models that predicted 363 death or hospitalization from HF determined renal function is one of the most significant factors in these outcomes²⁴. Renal function was included in the CHARM score through 364 365 serum sodium and creatinine. Multiple studies have demonstrated worsened short-term mortality for HF patients related to low serum sodium^{25,26}. Creatinine is a standard 366 367 measure of renal function, often used as a surrogate for eGFR. While eGFR was 368 considered as a measure of renal function, it is not a value directly recorded in the 369 SRTR database and can be calculated differently by institutions. Both age and BNP are also known prognostic factors in severe HF patients¹⁷. While age influences a variety of 370 371 physiological processes, advanced age in HF (>65 years) affects vascular resistance 372 and heart rate responsiveness, likely due to increased circulating norepinephrine levels²⁷. BNP is a biomarker exclusively produced by cardiac tissue. It serves as an 373 374 objective marker of cardiac stretch since it is influenced by level of end-diastolic volume, and it can also be an indicator of responsiveness to diuretic management 28 . 375 376

In addition to physiologic data, indicator variables such as previous cardiac surgery, previous cardiac transplant, ventilator support, and life support proved to be large contributors to pre-transplant mortality. These interventions often serve as a "bridge" to transplant, reserved for the most critically ill patients. Previous cardiac surgeries or transplants are also indicative of a more extensive history of cardiac illness. We specifically chose not to include variables that depend upon a physician's practice or measurement, such as right heart catheterization data or the level of inotropic support.

These variables were excluded with the intent of reducing bias based on treatmentvariation.

386

387 Though we present accurate predictive models, they must be viewed through the 388 confines of the study limitations, including sample size and missing data. Sample size 389 was dependent on the availability of data within the SRTR, reduced to 1,965 390 participants to account for missing laboratory variables. A thorough missingness 391 analysis was performed to account for selection biases; however, a larger population 392 with complete laboratory data would increase the power of these models. Additionally, 393 variables chosen for the model were limited by the type of data recorded within SRTR. 394 As such, certain serum markers were not readily available within the database and 395 therefore could not be used. Similarly, the specificity of some variables was limited. For 396 example, the term "Life Support" is broad and included anyone on inotropic support 397 alone or varying degrees of temporary or durable mechanical support. Therefore, "Life 398 Support" currently serves as a binary variable within the model, understanding that 399 different modalities of mechanical support may contribute differently to patient risk. The 400 next steps for further utilization of the CHARM score will include simulation modeling 401 and a prospective, multi-center validation study in which these additional variables are 402 collected and analyzed.

403

404 **Conclusion**

405 The Colorado Heart failure Acuity Risk Model (CHARM) score provides a novel,

406 validated model with strong positive predictive value for short-term mortality among

407	patients waitlisted for cardiac transplantation. We anticipate the CHARM score will be
408	useful in the era of continuous distribution to standardize organ allocation by providing
409	an objective and intuitive system for stratifying waitlisted heart failure patients based on
410	medical urgency.

- 411
- 412 **Author Contributions:** John Stephen Malamon (JSM) had full access to all the data in
- 413 the study and takes responsibility for the integrity of the data and the accuracy of the
- 414 data analysis.
- 415 Concept and design: JSM
- 416 Acquisition and analysis of data: JSM
- 417 Interpretation of data: All authors.
- 418 Drafting of the manuscript: RDM, SYP, JRHH, JSM
- 419 *Critical revision of the manuscript:* All authors.
- 420 Statistical analysis: JSM
- 421 Obtained funding: BK, JRHH
- 422 Administrative, technical, or material support: RDM, JSM
- 423 Supervision: BK, JRHH, JSM
- 424

425 **CONFLICTS OF INTEREST:**

426 The authors do not have any conflicts of interest to disclose.

427

428 **ACKNOWLEDGMENT:** The authors have not acknowledgment to make.

429

430 **5. REFERENCES:**

- 431 1. Stevenson LW. Crisis Awaiting Heart Transplantation: Sinking the Lifeboat. JAMA Intern
- 432 Med 2015;175(8):1406-9. DOI: 10.1001/jamainternmed.2015.2203.
- 433 2. Maitra NS, Dugger SJ, Balachandran IC, Civitello AB, Khazanie P, Rogers JG. Impact of
- 434 the 2018 UNOS Heart Transplant Policy Changes on Patient Outcomes. JACC Heart
- 435 Fail 2023;11(5):491-503. DOI: 10.1016/j.jchf.2023.01.009.
- 436 3. Cogswell R, John R, Estep JD, et al. An early investigation of outcomes with the new
- 437 2018 donor heart allocation system in the United States. J Heart Lung Transplant
- 438 2020;39(1):1-4. DOI: 10.1016/j.healun.2019.11.002.
- 439 4. Kilic A, Hickey G, Mathier MA, et al. Outcomes of the First 1300 Adult Heart Transplants
- in the United States After the Allocation Policy Change. Circulation 2020;141(20):1662-
- 441 1664. DOI: 10.1161/CIRCULATIONAHA.119.045354.
- 442 5. Pelzer KM, Zhang KC, Lazenby KA, et al. The Accuracy of Initial U.S. Heart Transplant
 443 Candidate Rankings. JACC Heart Fail 2023;11(5):504-512. DOI:
- 444 10.1016/j.jchf.2023.02.005.
- 445 6. Lin EY, Cohen HW, Bhatt AB, et al. Predicting Outcomes Using the Heart Failure
- 446 Survival Score in Adults with Moderate or Complex Congenital Heart Disease. Congenit
- 447 Heart Dis 2015;10(5):387-95. DOI: 10.1111/chd.12229.
- 448 7. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of
 449 survival in heart failure. Circulation 2006;113(11):1424-33. DOI:
- 450 10.1161/CIRCULATIONAHA.105.584102.
- 451 8. Goda A, Williams P, Mancini D, Lund LH. Selecting patients for heart transplantation:
- 452 comparison of the Heart Failure Survival Score (HFSS) and the Seattle heart failure
- 453 model (SHFM). J Heart Lung Transplant 2011;30(11):1236-43. DOI:
- 454 10.1016/j.healun.2011.05.012.

- 455 9. Lustig DB, Rodriguez R, Wells PS. Implementation and validation of a risk stratification
- 456 method at The Ottawa Hospital to guide thromboprophylaxis in ambulatory cancer
- 457 patients at intermediate-high risk for venous thrombosis. Thromb Res 2015;136(6):1099-
- 458 102. DOI: 10.1016/j.thromres.2015.08.002.
- 459 10. Pocock SJ, Ariti CA, McMurray JJ, et al. Predicting survival in heart failure: a risk score
- 460 based on 39 372 patients from 30 studies. Eur Heart J 2013;34(19):1404-13. DOI:
- 461 10.1093/eurheartj/ehs337.
- 462 11. Austin MT, Poulose BK, Ray WA, Arbogast PG, Feurer ID, Pinson CW. Model for end-
- 463 stage liver disease: did the new liver allocation policy affect waiting list mortality? Arch
- 464 Surg 2007;142(11):1079-85. DOI: 10.1001/archsurg.142.11.1079.
- 465 12. OPTN. A Guide to Calculating and Interpreting the Estimated Post-Transplant Survival
- 466 (EPTS) Score Used in the Kidney Allocation System (KAS). April 21, 2020
- 467 (<u>https://optn.transplant.hrsa.gov/media/1511/guide_to_calculating_interpreting_epts.pdf</u>).
- 468 13. Johnston R, Jones K, Manley D. Confounding and collinearity in regression analysis: a
- 469 cautionary tale and an alternative procedure, illustrated by studies of British voting

470 behaviour. Qual Quant 2018;52(4):1957-1976. DOI: 10.1007/s11135-017-0584-6.

- 471 14. Svetnik V, Liaw A, Tong C, Culberson JC, Sheridan RP, Feuston BP. Random forest: a
- 472 classification and regression tool for compound classification and QSAR modeling. J
- 473 Chem Inf Comput Sci 2003;43(6):1947-58. DOI: 10.1021/ci034160g.
- 474 15. Colvin M, Smith JM, Ahn Y, et al. OPTN/SRTR 2020 Annual Data Report: Heart. Am J
- 475 Transplant 2022;22 Suppl 2:350-437. DOI: 10.1111/ajt.16977.
- 476 16. Miller PE, Mullan CW, Chouairi F, et al. Mechanical ventilation at the time of heart
- 477 transplantation and associations with clinical outcomes. Eur Heart J Acute Cardiovasc
- 478 Care 2021;10(8):843-851. DOI: 10.1093/ehjacc/zuab063.

- 479 17. Santaguida PL, Don-Wauchope AC, Oremus M, et al. BNP and NT-proBNP as
- 480 prognostic markers in persons with acute decompensated heart failure: a systematic
- 481 review. Heart Fail Rev 2014;19(4):453-70. DOI: 10.1007/s10741-014-9442-y.
- 482 18. Cox DR. Regression Models and Life-Tables. Breakthroughs in Statistics Methodology
 483 and Distribution. New York: Springer; 1992:527-541.
- 484 19. Harrell FE, Jr., Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical
- 485 tests. JAMA 1982;247(18):2543-6. (<u>https://www.ncbi.nlm.nih.gov/pubmed/7069920</u>).
- 486 20. Malamon JS, Jackson WE, Saben JL, et al. A model for calculating the long-term
- 487 estimated post-transplant survival of deceased donor liver transplant patients.
- 488 EBioMedicine 2023;90:104505. DOI: 10.1016/j.ebiom.2023.104505.
- 489 21. Team RC. R: A language and environment for statistical computing (Version 4.0. 2). R
- 490 Foundation for Statistical Computing 2020.
- 491 22. Pedersen AB, Mikkelsen EM, Cronin-Fenton D, et al. Missing data and multiple
- 492 imputation in clinical epidemiological research. Clin Epidemiol 2017;9:157-166. DOI:
- 493 10.2147/CLEP.S129785.
- 494 23. Evans MD, Diaz J, Adamusiak AM, et al. Predictors of Survival After Liver
- 495 Transplantation in Patients With the Highest Acuity (MELD >/=40). Ann Surg
- 496 2020;272(3):458-466. DOI: 10.1097/SLA.00000000004211.
- 497 24. Rahimi K, Bennett D, Conrad N, et al. Risk prediction in patients with heart failure: a
- 498 systematic review and analysis. JACC Heart Fail 2014;2(5):440-6. DOI:
- 499 10.1016/j.jchf.2014.04.008.
- 500 25. Gheorghiade M, Abraham WT, Albert NM, et al. Relationship between admission serum
- 501 sodium concentration and clinical outcomes in patients hospitalized for heart failure: an
- 502 analysis from the OPTIMIZE-HF registry. Eur Heart J 2007;28(8):980-8. DOI:
- 503 10.1093/eurheartj/ehl542.

- 504 26. Klein L, O'Connor CM, Leimberger JD, et al. Lower serum sodium is associated with
- 505 increased short-term mortality in hospitalized patients with worsening heart failure:
- 506 results from the Outcomes of a Prospective Trial of Intravenous Milrinone for
- 507 Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation
- 508 2005;111(19):2454-60. DOI: 10.1161/01.CIR.0000165065.82609.3D.
- 509 27. Cody RJ, Torre S, Clark M, Pondolfino K. Age-related hemodynamic, renal, and
- 510 hormonal differences among patients with congestive heart failure. Arch Intern Med
- 511 1989;149(5):1023-8. (<u>https://www.ncbi.nlm.nih.gov/pubmed/2655542</u>).
- 512 28. Mueller C, McDonald K, de Boer RA, et al. Heart Failure Association of the European
- 513 Society of Cardiology practical guidance on the use of natriuretic peptide concentrations.
- 514 Eur J Heart Fail 2019;21(6):715-731. DOI: 10.1002/ejhf.1494.

516 **FIGURE LEGENDS**:

517

518 **Figure 1. Correlation Heatmap of Independent Variables.** Pearson's correlation

519 coefficients were calculated using all patients (N=1,965) and independent variables

520 (N=12) used to construct the three models (30D, 90D, and 1Y). This is used to provide a

521 measure of collinearity. Blue indicates a positive correlation, and red indicates a

522 negative correlation. The color saturation and circle area increase as the correlation

- 523 coefficients increase in magnitude.
- 524

525 Figure 2. Calibration Plots for 30-day, 90-day, and 1-year Models. Patient risk

526 scores (PRS) were calculated for all patients in the discovery cohort (N=1,179) and are

527 provided as a function of observed patient mortality rate per tier for the 30-day, 90-day, 528 and 1-year models. 30-day, 90-day, and 1-year models are labeled A, B, and C,

528 and 1-year models. 30-day, 90-day, and 1-year models are labeled A, B, and C,

respectively. The goodness-of-fit (R) was calculated using linear regression and was greater than 0.99 for all three models.

530

532 Figure 3. Area Under the Receiver Operating Characteristic Curve using

533 **Interaction Terms.** Logistic regression was performed using the generalized linear

534 model with interaction terms for the 30-day (Å), 90-day (B), and 1-year (C) models. The

535 area under the receiver operating characteristic curve or AUC was reported at 0.964,

- 536 0.904, and 0.78 for the 30-day, 90-day, and 1-year models, respectively.
- 537

TABLES:

		Discovery	Validation	All (N=1.965)	p-value
		(N=1,179)	(N=786)		pruide
Age					
	Mean (SD)	48.9 (14.6)	47.8 (14.2)	48.5 (14.5)	0.243
	Median [Min, Max]	53.0 [18.0, 74.0]	50.0 [18.0, 73.0]	52.0 [18.0, 74.0]	
Sex	I			1	1
	Female	312 (26.6%)	214 (27.3%)	526 (26.9%)	0.94
	Male	862 (73.4%)	570 (72.7%)	1432 (73.1%)	
Race	I		1	1	1
	Caucasian	851 (72.5%)	551 (70.3%)	1402 (71.6%)	0.995
	Hispanic/Latino	57 (4.9%)	47 (6.0%)	104 (5.3%)	
	Black or African	222 (18.9%)	152 (19.4%)	374 (19.1%)	
	American				
	Asian	31 (2.6%)	25 (3.2%)	56 (2.9%)	
	American Indian or	4 (0.3%)	2 (0.3%)	6 (0.3%)	
	Alaska Native				
	Native Hawaiian or	5 (0.4%)	4 (0.5%)	9 (0.5%)	
	Pacific Islander				
Ethnicity	, I			1	1
	Latino	59 (5.0%)	47 (6.0%)	106 (5.4%)	0.65
	Non-Latino or	1115 (95.0%)	737 (94.0%)	1852 (94.6%)	
	unknown				
Educatio	n			1	
	High School (9-12)	394 (33.6%)	252 (32.1%)	646 (33.0%)	0.994
	Attended	324 (27.6%)	225 (28.7%)	549 (28.0%)	
	College/Technical				
	School				
	Associate/Bachelor	251 (21.4%)	164 (20.9%)	415 (21.2%)	
	Degree				
	Post-college	114 (9.7%)	88 (11.2%)	202 (10.3%)	
	Graduate Degree				
	Grade School (0-8)	21 (1.8%)	15 (1.9%)	36 (1.8%)	
	None	70 (6.0%)	40 (5.1%)	110 (5.6%)	

Independen	t Variables							
Albumin								
	Mean (SD)	3.59 (0.578)	3.59 (0.611)	3.59 (0.591)	0.991			
	Median [Min, Max]	3.60 [1.70, 6.40]	3.60 [0.7, 6.50]	3.60 [0.7, 6.50]				
AST	I	1		I				
	Mean (SD)	39.4 (74.0)	39.8 (83.1)	39.6 (77.7)	0.993			
	Median [Min, Max]	27.0 [0.1, 1640]	26.0 [0.1, 1810]	26.5 [0.1, 1810]				
Bilirubin			1					
	Mean (SD)	0.975 (1.83)	1.09 (1.77)	1.02 (1.80)	0.377			
	Median [Min, Max]	0.7 [0.1, 40.6]	0.7 [0.1, 34.7]	0.7 [0.1, 40.6]				
BNP								
	Mean (SD)	1690 (2280)	1560 (2180)	1640 (2240)	0.478			
	Median [Min, Max]	776 [0, 10000]	696 [5, 10000]	741 [0, 10000]				
Cardiac Sur	gery	1						
	Yes	506 (43.1%)	332 (42.3%)	838 (42.8%)	0.947			
	No	668 (56.9%)	452 (57.7%)	1120 (57.2%)				
Creatinine	•	I	1					
	Mean (SD)	1.49 (1.16)	1.53 (1.14)	1.51 (1.15)	0.725			
	Median [Min, Max]	1.24 [0.2, 16.1]	1.25 [0.14, 10.8]	1.25 [0.14, 16.1]				
Circulatory	Support							
	Yes	436 (37.1%)	296 (37.8%)	732 (37.4%)	0.962			
	No	738 (62.9%)	488 (62.2%)	1226 (62.6%)				
Previous Transplant								
	Yes	97 (8.3%)	75 (9.6%)	172 (8.8%)	0.607			
	No	1077 (91.7%)	709 (90.4%)	1786 (91.2%)				
Sodium			1	1				
	Mean (SD)	135 (4.39)	135 (4.63)	135 (4.50)	0.13			
	Median [Min, Max]	136 [117, 150]	136 [109, 149]	136 [109, 150]				
Ventilator								
	Yes	18 (1.5%)	5 (0.6%)	23 (1.2%)	0.197			
	No	1156 (98.5%)	779 (99.4%)	1935 (98.8%)				
Waitlist Day	'S							
	Mean (SD)	260 (388)	268 (412)	263 (398)	0.899			
	Median [Min, Max]	110 [1.00, 4090]	119 [1.00, 3370]	113 [1.00, 4090]				
AST=aspartate aminotransferase; BNP=Brain natriuretic peptide								

Tier	30-day Precision (PPV)	90-day Precision	1-year Precision
7	0.983	0.942	0.857
6	0.987	0.927	0.862
5	0.989	0.924	0.825
4	0.993	0.837	0.668
3	0.986	0.969	0.966
2	1.0	0.985	0.985
1	1.0	1.0	1.0

Table 2. Tier Risk Index Precision for 30-day, 90-day, and 1-year Mortality Models

PPV = Positive Predictive Value



541 Figure 1. Correlation Heatmap of Independent Variables.







Figure 3. Area Under the Receiver Operating Characteristic Curve using Interaction terms.







	CAN_AGE_AT_LISTING	CAN_CARDIAC_SURG	CAN_LIFE_SUPPORT	CAN_PREV_TX	CAN_VENTILATOR	CANHX_LAB_ALBUMIN	CANHX_LAB_BILI	CANHX_LAB_BNP	CANHX_LAB_SERUM_CREAT	CANHX_LAB_SGOT	CANHX_LAB_SODIUM	wl.days		4
CAN_AGE_AT_LISTING	1	-0.05	-0.05	-0 <mark>.2</mark> 1	-0.01	-0 <mark>.1</mark> 8	-0.06	-0.02	0.12	-0.02	0.04	-0.04		
CAN_CARDIAC_SURG	-0.05	1	-0.02	-0.03	0.03	0.06	0	-0.05	-0.04	-0.04	-0.06	0.05		0.8
CAN_LIFE_SUPPORT	-0.05	-0.02	1	-0.01	0.14	-0.04	0.01	0.09	0.01	-0.03	-0 <mark>.1</mark> 3	-0.11	·	0.6
CAN_PREV_TX	-0 <mark>.2</mark> 1	-0.03	-0.01	1	0.03	0.08	-0.04	0.07	0.17	-0.04	0.14	-0.02		0.4
CAN_VENTILATOR	-0.01	0.03	0.14	0.03	1	-0.05	0	0.07	-0.01	0.01	0.01	-0.02		0.2
CANHX_LAB_ALBUMIN	-0 <mark>.1</mark> 8	0.06	-0.04	0.08	-0.05	1	-0.09	-0.06	-0.08	-0.06	0.13	0.09		0
CANHX_LAB_BILI	-0.06	0	0.01	-0.04	0	-0.09	1	0.05	0.04	0.13	-0.1	-0.05		0
CANHX_LAB_BNP	-0.02	-0.05	0.09	0.07	0.07	-0.06	0.05	1	0.12	0.03	-0.02	-0.04		-0.2
CANHX_LAB_SERUM_CREAT	0.12	-0.04	0.01	0.17	-0.01	-0.08	0.04	0.12	1	0.01	-0.04	0.01		-0.4
CANHX_LAB_SGOT	-0.02	-0.04	-0.03	-0.04	0.01	-0.06	0.13	0.03	0.01	1	-0.06	-0.03		-0.6
CANHX_LAB_SODIUM	0.04	-0.06	-0 <mark>.1</mark> 3	0.14	0.01	0.13	- 0. 1	-0.02	-0.04	-0.06	1	0.07		-0.8
wl.days	-0.04	0.05	-0 <mark>.1</mark> 1	-0.02	-0.02	0.09	-0.05	-0.04	0.01	-0.03	0.07	1		1